BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products, is working on changing the grim reality caused by the evolution of COVID-19. “The company’s leading inhaled nanosized antibody (‘NanoAb’) candidate, which is currently being prepared for clinical trials, has shown neutralization of all relevant Omicron subvariants… Developed in collaboration with Germany-based Max Planck Institute for Multidisciplinary Sciences (‘MPI’) and the University Medical Center Göttingen (‘UMG’), the alpaca-derived NanoAbs have demonstrated unique characteristics such as greater formulation advantages, stability at high temperatures, and binding affinity than monoclonal antibodies (‘mAbs’). Moreover, NanoAbs have shown strong potential for superior clinical outcomes, safety and patient convenience at lower costs than mAbs, which have generated billions in annual commercial sales,” a recent article reads. “Indeed, the emergence of new variants remains a concern, and NanoAb therapeutics have the potential to quickly and effectively address new variants,” CEO Amir Reichman is quoted as saying. “Our collaborators [at MPI and UMG] have generated libraries each with ~300 million COVID-19 NanoAb candidates, as compared to mAb libraries that contain only thousands of options. Thus, as new variants emerge, we would expect to be in a position to rapidly develop a new neutralizing NanoAb.”
To view the full article, visit https://ibn.fm/SFL4r
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.